FCGR3A and COVID-19: We found the expansion of myeloid DCs, CD14+ monocytes, and MP/platelets in most of the patients with COVID-19, and decreased CD16+ monocytes and NKs in more than half of the patients with COVID-19 (Fig. 1e).